Hormone therapy and breast cancer risk: Trumping fear with facts

Menopause

Volumn 13, Issue 2, 2006, Pages 160-163

  Kaunitz, Andrew M ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEAR; FEMALE; FLORIDA; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PHYSICIANS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 33646803851     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000196814.41871.ff     Document Type: Editorial

References (27)

1. American Cancer Society. Cancer facts and figures 2005. Available at: http://www.cancer.org/downloads/stt/caff2005f4pwsecured.pdf. Accessed October 20, 2005.
2. American Cancer Society. Breast cancer facts and figures 2005-2006. Available at: http://www.cancer.org/downloads/stt/caff2005brf.pdf. Accessed October 20, 2005.
3. Society for Women's Health Research. Women's fear of heart disease has almost doubled in three years, but breast cancer remains most feared disease. http://www.womenshealthresearchorg/press/releases/070705.htm. Accessed October 20, 2005.
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1-4.
5. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-323.
6. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
7. Gertig DM, Fletcher AS, English DR, et al. Hormone therapy and breast cancer: what factors modify the association? Menopause 2006;13:178-184.
8. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004;45:S3-S9.
9. Williams RS, Christie D, Sistrom C. Assessment of the understanding of the risks and benefits of hormone replacement therapy (HRT) in primary care physicians. Am J Obstet Gynecol 2005;193:551-558.
10. The North American Menopause Society. Recommendations for estrogen and progestin use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004;11:589-600.
11. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-1712.
12. Barrett-Connor E, Grady D, Stefanick M. The rise and fall of menopausal hormone therapy. Annu Rev Public Health 2005;26:115-140.
13. Hulley SB, Grady D. The WHI estrogen-alone trial: do things look any better? JAMA 2004;291:1769-1771.
14. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-1158.
15. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-3263.
16. Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-1392.
17. Li CI. Postmenopausal hormone therapy and the risk of breast cancer: The view of an epidemiologist. Maturitas 2004;49:44-50.
18. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast cancer risk following long-term oestrogen-and oestrogen-progestin- replacement therapy. Int J Cancer 1999;81:339-344.
19. Sturdee DW, Rantala ML, Colau JC, Zahradnik HP, Riphagen FE, Multicenter MLS Investigators. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric 2004;7:404-411.
20. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
21. American College of Obstetricians and Gynecologists. Hormone therapy. Obstet Gynecol 2004;104(Suppl):1S-131S.
22. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253.
23. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353:1773-1783.
24. Speroff L. Postmenopausal hormone therapy and breast cancer. Endocrine 2004;24:211-216.
25. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-1376.
26. Harvey J, Scheurer C, Kowakami FT, Quebe-Fehling E, Ibarra de Palacios P, Ragavan W. Hormone replacement therapy and breast density changes. Climacteric 2005;8:185-192.
27. Banks E, Reeves G, Beral V, et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 2004;329:477-483.